Gastric Cancer Clinical Trial Tracker — Monitor Stomach Cancer and GEJ Adenocarcinoma Trials

Why gastric cancer trial monitoring matters in 2026

Gastric and gastroesophageal junction (GEJ) adenocarcinoma is the fifth most common cancer worldwide, with over one million new cases annually. While incidence is declining in Western populations, it remains extremely prevalent in East Asia (Japan, Korea, China), and the majority of patients present with advanced disease and poor prognosis.

The gastric cancer pipeline in 2026 is undergoing a transformation driven by several converging targets:

• CLDN18.2 (Claudin 18.2) — zolbetuximab (Vyloy) received FDA approval in 2024 for CLDN18.2-positive, HER2-negative gastric/GEJ cancer. This marks the validation of CLDN18.2 as a key target; ADCs, bispecifics, and CAR-T cells targeting CLDN18.2 are now pouring into trials
• HER2-targeted ADCs — trastuzumab deruxtecan (T-DXd / Enhertu) has shown transformative activity in HER2-positive gastric cancer, displacing standard HER2 therapy. Multiple next-gen HER2 ADCs are in development
• PD-1/PD-L1 combinations — nivolumab (CheckMate 649), pembrolizumab, and tislelizumab are now first-line standards in high CPS tumors; ongoing trials are defining maintenance, combination, and biomarker strategies
• FGFR2b inhibitors — bemarituzumab (anti-FGFR2b) showed Phase 3 activity in FGFR2b-overexpressing tumors; approval expected imminently
• VEGFR2 and anti-angiogenic — ramucirumab remains active; combinations with IO being explored
• EGFR and MET-targeted agents — in molecularly selected subpopulations

What we monitor for gastric cancer

Our system pulls from the ClinicalTrials.gov API every day. For a gastric cancer watch profile, you can configure alerts for:

• Condition keywords: "gastric cancer", "stomach cancer", "gastroesophageal junction", "GEJ adenocarcinoma", "gastric adenocarcinoma", "gastroesophageal cancer"
• Drug/target keywords: "CLDN18.2", "claudin 18", "zolbetuximab", "HER2 gastric", "trastuzumab deruxtecan", "FGFR2b", "bemarituzumab", "ramucirumab" — any drug or target you're tracking
• Phase filter: Phase 1 for early programs, Phase 2/3 for competitive commercial data
• Sponsor type: Industry only or all sponsors including major academic sites in East Asia and the US
• Status changes: New registrations, enrollment opens, status updates, and results postings

CLDN18.2: the new defining target in gastric cancer

The approval of zolbetuximab (anti-CLDN18.2 monoclonal antibody) in 2024 triggered a race among ADC, bispecific, and cellular therapy developers to target Claudin 18.2. The key competitive dynamics:

• CLDN18.2 ADCs: CMG901 (AstraZeneca/Keymed), RC108 (RemeGen), and multiple other programs in Phase 1/2 — next wave after zolbetuximab
• Bispecific antibodies: CLDN18.2 × 4-1BB, CLDN18.2 × CD3 bispecifics in early trials
• CAR-T cells: CLDN18.2-directed CAR-T is entering Phase 1/2 in China and the US
• Combination with PD-1: Zolbetuximab plus IO combinations now entering trials

Monitoring ClinicalTrials.gov weekly gives competitive intelligence teams a 4–8 week lead over conference presentations on new CLDN18.2 program initiations.

Who uses gastric cancer trial monitoring

• GI oncology BD teams — tracking CLDN18.2, HER2, and FGFR2b competitor programs for partnering and pipeline decisions
• Oncology investors — monitoring Phase 2/3 initiations and enrollment milestones in gastric cancer
• GI oncologists and research sites — staying current on available trials for patients with advanced gastric/GEJ cancer
• CROs with GI oncology practices — tracking competing enrollment across the major Phase 3 gastric programs
• Academic researchers in gastric oncology — following the global competitive landscape including East Asian programs

How TrialNotify works

We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.

Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.

Pricing

Free: 1 disease/keyword profile, daily email digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, phase and sponsor filters.

Pro — $149/month: Unlimited profiles, priority email delivery, digest frequency options. Best for BD teams and investors.